Fair Value Measurements (Details 2) (USD $)	6 Months Ended				3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014 Convertible Debt [Member]	Feb. 14, 2014 Convertible Debt [Member]	Jun. 30, 2014 Fair Value Inputs Level2 [Member] Convertible Debt [Member]	Jun. 30, 2014 Access Pharmaceuticals Inc [Member] Licensing Agreements [Member]	Jun. 30, 2014 Access Pharmaceuticals Inc [Member] Licensing Agreements [Member]	Jun. 30, 2014 Access Pharmaceuticals Inc [Member] Licensing Agreements [Member] Fair Value Inputs Level3 [Member]	Jun. 30, 2014 Access Pharmaceuticals Inc [Member] Licensing Agreements [Member] Minimum [Member]	Jun. 30, 2014 Access Pharmaceuticals Inc [Member] Licensing Agreements [Member] Maximum [Member]
Reconciliation of contingent consideration obligations related to acquisition of MuGard rights
Balance at beginning of period						$ 14,550,000
Payments made						(90,000)
Adjustments to fair value of contingent consideration	1,178,000				400,000	1,178,000
Other adjustments						103,000
Balance at end of period					15,741,000	15,741,000
Estimated undiscounted royalty amounts payable								28,000,000	34,000,000
Period over which estimated undiscounted royalty amounts could be paid						10 years
Discount rate (as a percent)							15.00%
Contingent consideration classified as short-term liability					1,600,000	1,600,000
Aggregate principal amount of notes issued			200,000,000
Interest rate (as a percent)	2.50%	2.50%
Estimated fair value of the Notes	$ 211,300,000			$ 211,300,000